$174.40
0.35% today
Nasdaq, Nov 04, 09:12 pm CET
ISIN
US09062X1037
Symbol
BIIB
Sector
Industry

Biogen Stock News

Neutral
Schaeffers Research
7 days ago
Biotechnology firm Biogen Inc (NASDAQ:BIIB) is scheduled to report third-quarter results before the open on Wednesday, Oct. 30.
Neutral
Reuters
7 days ago
Biogen said on Monday insider Robin Kramer would take over as its chief financial officer after Michael McDonnell plans to retire from the post in February 2025.
Neutral
GlobeNewsWire
9 days ago
CAMBRIDGE, Mass., Oct. 26, 2024 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) – today presented complete results from the Phase 2 IGNAZ study evaluating felzartamab, an investigational anti-CD38 monoclonal antibody, in people living with IgA nephropathy (IgAN). The results showed substantial reductions in proteinuria, stabilization of kidney function, and sustained treatment effect more than 1...
Neutral
GlobeNewsWire
11 days ago
CAMBRIDGE, Mass., Oct. 24, 2024 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) announced upcoming data presentations and programming at the Clinical Trials on Alzheimer's Disease (CTAD) annual conference, taking place October 29 - November 1, in Madrid, Spain. The presentations will include updates on new scientific findings from Biogen's Alzheimer's portfolio, highlighting data on different as...
Neutral
GlobeNewsWire
13 days ago
CAMBRIDGE, Mass., Oct. 22, 2024 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) – announced the company will present a variety of new data from its felzartamab clinical development program at Kidney Week 2024, the American Society of Nephrology's (ASN) annual meeting, taking place October 23-27 in San Diego, California. Felzartamab, an investigational anti-CD38 monoclonal antibody, is a potentia...
Positive
MarketBeat
25 days ago
The stock market's impressive and resilient performance in 2024, with the SPDR S&P 500 ETF NYSE: SPY up over 21% YTD and trading at all-time highs, has led many investors to chase high-flying stocks at all-time highs. However, this approach can be risky as stocks stretched to the upside might face corrections.
Positive
Market Watch
26 days ago
Biogen stock was headed higher Wednesday, to bounce off an 11-year closing low, after the biotechnology company received positive news from regulators about its treatment for kidney-transplant rejections.
Neutral
GlobeNewsWire
26 days ago
CAMBRIDGE, Mass., Oct. 09, 2024 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) – Biogen announced today that felzartamab, an investigational anti-CD38 monoclonal antibody, has received Breakthrough Therapy Designation (BTD) from the U.S. Food and Drug Administration (FDA) for the treatment of late antibody-mediated rejection (AMR) without T-cell mediated rejection in kidney transplant patients....

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today